United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mitozantrone hydrochloride, quantity: 23.284 mg (equivalent: mitozantrone, qty 20 mg) - injection, solution - excipient ingredients: water for injections; sodium acetate; sodium sulfate; nitrogen; dilute hydrochloric acid; glacial acetic acid; sodium chloride - the treatment of metastatic carcinoma of the breast, non-hodgkin's lymphoma, adult acute non-lymphocytic leukaemia (anll) and chronic myelogenous leukaemia in blast crisis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mitozantrone hydrochloride, quantity: 11.642 mg (equivalent: mitozantrone, qty 10 mg) - injection, solution - excipient ingredients: sodium sulfate; glacial acetic acid; sodium acetate; dilute hydrochloric acid; sodium chloride; nitrogen; water for injections - the treatment of metastatic carcinoma of the breast, non-hodgkin's lymphoma, adult acute non-lymphocytic leukaemia (anll) and chronic myelogenous leukaemia in blast crisis.

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - daunorubicin - powder for injection - daunorubicin 20 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

daunorubicin -

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - ondansetron - solution for injection - 2 milligram(s)/millilitre - serotonin (5ht3) antagonists; ondansetron

Israel - English - Ministry of Health

novartis israel ltd - ondansetron as hydrochloride dihydrate - solution for injection - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ≥6 months, and for the prevention and treatment of ponv in children aged ≥ 1 month.

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises ltd - ondansetron - solution for injection - 2 milligram(s)/millilitre - serotonin (5ht3) antagonists; ondansetron

Malta - English - Medicines Authority

accord healthcare limited - ondansetron - solution for infusion or injection - ondansetron 2 mg/ml - antiemetics and antinauseants

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride injection, usp has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms'  tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. patients should not be treated with doxorubicin if they have any of the following conditions: baseline neutrophil count <1,500 cells/mm 3 ; severe hepatic impairment; recent myocardial infarction; severe myocardial insufficiency; severe arrhythmias; previous treatment with complete cumulative doses of doxoru